|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Connell LC, Harding JJ and Abou-Alfa GK:
Advanced hepatocellular cancer: The current state of future
research. Curr Treat Options Oncol. 17:432016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Han KH, Kudo M, Ye SL, Choi JY, Poon RT,
Seong J, Park JW, Ichida T, Chung JW, Chow P and Cheng AL: Asian
consensus workshop report: Expert consensus guideline for the
management of intermediate and advanced hepatocellular carcinoma in
Asia. Oncology. 81:(Suppl 1). S158–S164. 2011. View Article : Google Scholar
|
|
5
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benson AB III, Abrams TA, Ben-Josef E,
Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica
MI, Davila R, et al: NCCN clinical practice guidelines in oncology:
Hepatobiliary cancers. J Natl Compr Canc Netw. 7:350–391. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM,
Poon RT, Fan ST and Wong J: Randomized controlled trial of
transarterial lipiodol chemoembolization for unresectable
hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi T, Ishiyama K and Ohdan H:
Prevention of recurrence after curative treatment for
hepatocellular carcinoma. Surg Today. 43:1347–1354. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al:
Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: A
randomised controlled trial. Lancet. 359:1734–1739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsuo N, Uchida H, Nishimine K, Soda S,
Oshima M, Nakano H, Nagano N, Nishimura Y, Yoshioka T, Guo Q, et
al: Segmental transcatheter hepatic artery chemoembolization with
iodized oil for hepatocellular carcinoma: Antitumor effect and
influence on normal tissue. J Vasc Interv Radiol. 4:543–549. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Higuchi T, Kikuchi M and Okazaki M:
Hepatocellular carcinoma after transcatheter hepatic arterial
embolization. A histopathologic study of 84 resected cases. Cancer.
73:2259–2267. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weintraub JL and Salem R: Treatment of
hepatocellular carcinoma combining sorafenib and transarterial
locoregional therapy: State of the science. J Vasc Interv Radiol.
24:1123–1134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ and
Cao GW: Increased expression of vascular endothelial growth factor
in hepatocellular carcinoma after transcatheter arterial
chemoembolization. Acta Radiol. 49:523–529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sergio A, Cristofori C, Cardin R, Pivetta
G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A and
Farinati F: Transcatheter arterial chemoembolization (TACE) in
hepatocellular carcinoma (HCC): The role of angiogenesis and
invasiveness. Am J Gastroenterol. 103:914–921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mantovani A, Garlanda C and Allavena P:
Molecular pathways and targets in cancer-related inflammation. Ann
Med. 42:161–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: Plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Capece D, Fischietti M, Verzella D,
Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F and Alesse E:
The inflammatory microenvironment in hepatocellular carcinoma: A
pivotal role for tumor-associated macrophages. Biomed Res Int.
2013:1872042013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Riabov V, Gudima A, Wang N, Mickley A,
Orekhov A and Kzhyshkowska J: Role of tumor associated macrophages
in tumor angiogenesis and lymphangiogenesis. Front Physiol.
5:752014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bingle L, Brown NJ and Lewis CE: The role
of tumour-associated macrophages in tumour progression:
Implications for new anticancer therapies. J Pathol. 196:254–265.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leek RD and Harris AL: Tumor-associated
macrophages in breast cancer. J Mammary Gland Biol Neoplasia.
7:177–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding T, Xu J, Wang F, Shi M, Zhang Y, Li
SP and Zheng L: High tumor-infiltrating macrophage density predicts
poor prognosis in patients with primary hepatocellular carcinoma
after resection. Hum Pathol. 40:381–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang
W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of
macrophage colony-stimulating factor in peritumoral liver tissue is
associated with poor survival after curative resection of
hepatocellular carcinoma. J Clin Oncol. 26:2707–2716. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chanmee T, Ontong P, Konno K and Itano N:
Tumor-associated macrophages as major players in the tumor
microenvironment. Cancers (Basel). 6:1670–1690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gupta S, Kobayashi S, Phongkitkarun S,
Broemeling LD and Kan Z: Effect of transcatheter hepatic arterial
embolization on angiogenesis in an animal model. Invest Radiol.
41:516–521. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weidner N: Current pathologic methods for
measuring intratumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thoeny HC, De Keyzer F, Vandecaveye V,
Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal
G, et al: Effect of vascular targeting agent in rat tumor model:
Dynamic contrast-enhanced versus diffusion-weighted MR imaging.
Radiology. 237:492–499. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Buadu LD, Murakami J, Murayama S,
Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S and Ohno S:
Breast lesions: Correlation of contrast medium enhancement patterns
on MR images with histopathologic findings and tumor angiogenesis.
Radiology. 200:639–649. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bharat A, Brown DB, Crippin JS, Gould JE,
Lowell JA, Shenoy S, Desai NM and Chapman WC: Pre-liver
transplantation locoregional adjuvant therapy for hepatocellular
carcinoma as a strategy to improve longterm survival. J Am Coll
Surg. 203:411–420. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duvoux C, Cherqui D, Van Nhieu JT,
Vavasseur D, Zafrani ES, Mathieu D, Fagniez PL and Dhumeaux D:
Chemoembolization for hepatocellular carcinoma in cirrhotic
patients: Assessment of efficacy on total hepatectomy specimens.
Transplant Proc. 26:3572–3573. 1994.PubMed/NCBI
|
|
31
|
Liao X, Yi J, Li X, Yang Z, Deng W and
Tian G: Expression of angiogenic factors in hepatocellular
carcinoma after transcatheter arterial chemoembolization. J
Huazhong Univ Sci Technolog Med Sci. 23:280–282. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zekri J, Mansour M and Karim SM: The
anti-tumour effects of zoledronic acid. J Bone Oncol. 3:25–35.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Green J and Lipton A: Anticancer
properties of zoledronic acid. Cancer Invest. 28:944–957. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rogers TL and Holen I: Tumour macrophages
as potential targets of bisphosphonates. J Transl Med. 9:1772011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Coscia M, Quaglino E, Iezzi M, Curcio C,
Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni
G, et al: Zoledronic acid repolarizes tumour-associated macrophages
and inhibits mammary carcinogenesis by targeting the mevalonate
pathway. J Cell Mol Med. 14:2803–2815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang
PY, Xu HX, Kong LQ, Wang L, Wu WZ and Tang ZY: Depletion of
tumor-associated macrophages enhances the effect of sorafenib in
metastatic liver cancer models by antimetastatic and antiangiogenic
effects. Clin Cancer Res. 16:3420–3430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Condeelis J and Pollard JW: Macrophages:
Obligate partners for tumor cell migration, invasion, and
metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
